Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...
“Patients with pulmonary edema generally describe breathlessness. Sometimes they feel like they are suffocating or breathing ...
The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...
Although more women than men have pulmonary arterial hypertension, several PAH medications are teratogenic, according to a ...
Patients who have comorbid COPD with heart failure and ischemic heart disease have increased health care resource use and higher mortality.
GlaxoSmithKline’s (GSK) Nucala (mepolizumab) has been approved by the MHRA to treat adults with uncontrolled chronic ...
Mount Sinai analysis looks at the effectiveness of electrocardiograms analyzed via deep learning as a tool for early COPD detection ...
AirNexis Therapeutics is a clinical-stage biotech company developing novel therapeutic drugs for the treatment of COPD patients. AN01 is a dual PDE3/4 inhibitor that exerts synergistic effects through ...
Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...
K-State experts outline how sudden pasture changes can trigger fog fever in adult cattle and share practical prevention ...
Insights from analysts' 12-month price targets are revealed, presenting an average target of $49.8, a high estimate of $52.00 ...
Systemic therapy for sarcoidosis is reserved for organ-threatening disease, and laryngeal involvement necessitates treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback